Skip to content

Efficacy and Safety of ultrasound-guided ropivacaine combined with dexmedetomidine in sacral canal block for catheter-related bladder discomfort after ureteroscopic lithotripsy :Aprospective,double-blind ,randomized,controlled study

Efficacy and Safety of ultrasound-guided ropivacaine combined with dexmedetomidine in sacral canal block for catheter-related bladder discomfort after ureteroscopic lithotripsy :Aprospective,double-blind ,randomized,controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500100507
Enrollment
Unknown
Registered
2025-04-10
Start date
2025-05-06
Completion date
Unknown
Last updated
2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter-related bladder discomfort

Interventions

Control group(C Group) Ropivacaine alone in sacral canal block group:Before general anesthesia induction, 0.35% ropivacaine 10 ml was given under ultrasound guided sacral canal block.
Trial group (I Group)Ropivacaine combined with dexmedetomidine in sacral canal block group:Before general anesthesia induction, 10 ml of dexmedetomidine1ug/kg and 0.35% ropivacaine were given under ul

Sponsors

Beijing Miyun District Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.ASA ?or ? grade; 2.Age 18 years or older; 3.Male patients with indwelling catheters after anesthesia; 4.Ureteroscopic lithotripsy under elective general anesthesia;

Exclusion criteria

Exclusion criteria: 1.Long-term use of anticoagulants for coagulation dysfunction, associated with neuromuscular diseases or sensory disorders,sacral canal block contraindications. 2.Mental disorders,cognitive disorders; 3.History of abnormal urethral morphology; 4.Urinary tract infection and urinary tract irritation; 5.Bladder dysfunction such as excessive bladder syndrome,neurogenic bladder dysfunction; 6.Benign Prostatic Hyperplasia; 7.History of narcotic analgesic drug dependence; 8.Refusing or unable to cooperate;

Design outcomes

Primary

MeasureTime frame
Incidence of catheter-related bladder discomfort 24 hours after surgery;

Secondary

MeasureTime frame
The occurrence of delirium;Bromage score;Agitation score;Nausea and vomiting;The use of remedial analgesics for postoperative catheter-related bladder discomfort pain;Catheter-related bladder discomfort severity rating;Ramsay sedation score;Visual analogue score(VAS);Sleep score;Duration of analgesia;

Countries

China

Contacts

Public ContactShao Lina

Beijing Miyun District Hospital

shaolina5566@163.com+86 18611329379

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026